Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

LINZ PHARMACEUTICALS (PVT) LTD.

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000540 53 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx53product presentations
G19generic molecules
DF6dosage-form groups
TA3therapeutic areas
PKR53current price records
REG47registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage98%
priced packs safely normalized per unit
Comparable-market coverage96%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixLINZ PHARMACEUTICALS (PVT) LTD.Share of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/linz-pharmaceuticals-pvt-ltdGenerated 10 Aug 2026Anti-infectives51 · 96%Vitamins, minerals & nutrition1 · 2%Gastrointestinal & hepatology1 · 2%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioLINZ PHARMACEUTICALS (PVT) LTD.Distribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/linz-pharmaceuticals-pvt-ltdGenerated 10 Aug 202653presentationsInjection27 · 51%Tablet15 · 28%Suspension6 · 11%Capsule3 · 6%Infusion1 · 2%Sachet1 · 2%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionLINZ PHARMACEUTICALS (PVT) LTD.Current company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/linz-pharmaceuticals-pvt-ltdGenerated 10 Aug 202651comparable productsBelow market median20 · 39%Near market median21 · 41%Above market median10 · 20%Company median price position-1.2%Lowest-price equivalents7Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsLINZ PHARMACEUTICALS (PVT) LTD.Companies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/linz-pharmaceuticals-pvt-ltdGenerated 10 Aug 2026Bosch Pharmaceuticals (Pvt) Ltd.19 shared100% overlapNeutro Pharma (Pvt.) Ltd.,18 shared95% overlapS.J & G. Fazul Ellahie (pvt) limite…17 shared89% overlapEpharm Laboratories17 shared89% overlapMedisave Pharmaceuticals17 shared89% overlapMacter International Limited16 shared84% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives51 products · 96%
Vitamins, minerals & nutrition1 products · 2%
Gastrointestinal & hepatology1 products · 2%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Third-generation cephalosporins14 products · 26%
Aminoglycoside antibacterials9 products · 17%
Antimalarials7 products · 13%
Macrolide antibacterials7 products · 13%
Fluoroquinolone antibacterials5 products · 9%
First-generation cephalosporins3 products · 6%
Second-generation cephalosporins3 products · 6%
Carbapenem antibacterials2 products · 4%
Formulation footprint

Dosage forms

Injection27 products
Tablet15 products
Suspension6 products
Capsule3 products
Infusion1 products
Sachet1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 AikaAmikacin 9presentations 1 g/4 mL, 100 mg/2 mL, 200 mg/100 mL, 25 mg · Injection, Infusion #2 ZelinzAzithromycin 7presentations 1 g, 100 mg/5 mL, 200 mg/5 mL, 250 mg · Sachet, Suspension, Capsule #3 QzonCeftriaxone 4presentations 1 g, 2 g, 250 mg, 500 mg · Injection #4 CezoCefazolin 3presentations 1 g, 250 mg, 500 mg · Injection #5 LinzimCefixime 3presentations 100 mg/5 mL, 400 mg · Suspension, Capsule #6 MiroximCefuroxime 3presentations 1.5 g, 250 mg, 750 mg · Injection
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median2039% of comparable products
Near market median21within ±5% of median
Above market median1020% of comparable products
Lowest-price equivalents7ties included
Company median price position -1.2% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Qlena 250 mgLevofloxacin · Tablet · 10's PKR 23.49/tablet-50.6% vs market median Ciplinz 250 mgCiprofloxacin · Tablet · 10’s PKR 13.59/tablet-46.2% vs market median Qlena 500 mgLevofloxacin · Tablet · 10's PKR 46.60/tablet-40.8% vs market median Linzim 100 mg/5 mLCefixime · Suspension · 60mL PKR 6.47/mL-38.3% vs market median Ciplinz 500 mgCiprofloxacin · Tablet · 10’s PKR 26.21/tablet-37.6% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Bosch Pharmaceuticals (Pvt) Ltd.250 products · 73 generics 19shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 18shared generics S.J & G. Fazul Ellahie (pvt) limited.193 products · 68 generics 17shared generics Epharm Laboratories144 products · 67 generics 17shared generics Medisave Pharmaceuticals117 products · 53 generics 17shared generics Macter International Limited248 products · 91 generics 16shared generics
Regulatory & price activity

Observed database signals

Registration numbers47
Price-history records57
Products with price history4
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date27 Jul 2026
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

51 results
Intelligence filter: Therapeutic areaAnti-infectives Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
Aika Amikacin 25 mg Injection 5's 048456 PKR 178.62 PKR 35.72/vial/unit 7% below median
Aika Amikacin 100 mg/2 mL Injection 1’s 048458 PKR 67.96 PKR 67.96/vial/unit 11% below median
Aika Amikacin 50 mg Injection 5's 048457 PKR 223.27 PKR 44.65/vial/unit 6% below median
Aika Amikacin 200 mg/100 mL IV infusion 1’s 048460 PKR 213.57 PKR 213.57/vial/unit No comparator
Aika Amikacin 25 mg/mL Solution for injection 1’s 048456 PKR 38.83 PKR 38.83/vial/unit Near median
Aika Amikacin 1 g/4 mL Injection 1’s 048461 PKR 403.83 PKR 403.83/vial/unit Near median
Aika Amikacin 250 mg/2 mL Injection 1’s 048459 PKR 116.49 PKR 116.49/vial/unit 15% below median
Aika Amikacin 100 mg/2 mL Injection 5's 048458 PKR 312.59 PKR 62.52/vial/unit 18% below median
Aika Amikacin 50 mg/mL Solution for injection 1’s 048457 PKR 48.54 PKR 48.54/vial/unit 6% below median
Cezo Cefazolin 1 g Injection 1’s 033806 PKR 213.57 PKR 213.57/vial/unit Near median
Cezo Cefazolin 250 mg Injection 1’s 033804 PKR 77.66 PKR 77.66/vial/unit Near median
Cezo Cefazolin 500 mg Injection 1’s 033805 PKR 116.49 PKR 116.49/vial/unit 5% below median
Ciplinz Ciprofloxacin 500 mg Tablet 10’s 048455 PKR 262.10 PKR 26.21/tablet 38% below median
Ciplinz Ciprofloxacin 250 mg Tablet 10’s 048454 PKR 135.90 PKR 13.59/tablet 46% below median
Dofmero Meropenem 1000 mg Injection 1's 112805 PKR 4,130.61 PKR 4,130.61/vial/unit Near median
Dofmero Meropenem 500 mg Injection 1's 112804 PKR 2,209.87 PKR 2,209.87/vial/unit 6% above median
Herme Artemether + Lumefantrine 40 mg + 240 mg Tablet 8's 061700 PKR 504.79 PKR 63.10/tablet Near median
Herme Artemether 80 mg Injection 1mL × 5's 096222 PKR 770.78 PKR 154.16/mL 13% below median
Herme Artemether + Lumefantrine 20 mg + 120 mg Tablet 16's 053427 PKR 621.28 PKR 38.83/tablet Near median
Herme Flash Artemether + Lumefantrine 20 mg + 120 mg Dispersible tablet 2 × 8's 096223 PKR 513.83 PKR 32.11/tablet 7% below median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.